Mizuho analyst Vikram Malhorta maintains Ventas (NYSE:VTR) with a Buy and lowers the price target from $65 to $61.
Allogene Therapeutics To Restate Previously Filed Financial Statements Related To The December 2020 Formation Of The Allogene Overland Biopharm Joint Venture In Asia; No Impact On Cash, Cash Equivalents And Marketable Investments, Cash Runway Or Busine…
No Impact on Cash, Cash Equivalents and Marketable Investments, Cash Runway or Business Operations Company Targeting On or Before March 14, 2024 to File Amended Financial Statements and Report Fourth Quarter and
